Patrick Campbell

Louis Pasquale, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, discusses how technology and artificial intelligence has been embraced by ophthalmology.

A presentation at AAO 2019 highlighted the ability of the EyeArt screening system to detect diabetic retinopathy with 95.5% sensitivity.

A study presented at AAO 2019 revealed that obstructive sleep apnea could be a risk factor for diabetic macular edema and refractory diabetic macular edema.

Results of a phase 1 study examining a potential gene therapy for x-linked retinitis pigmentosa showcased improvements in microperimetry and a favorable safety profile.

Raymond Douglas, MD, PhD, professor of ophthalmology and director of the Orbit and Thyroid Eye Disease Center at Cedars-Sinai, discusses results of the phase 3 OPTIC study and what a potential approval of teprotumumab would mean for patients and physicians.

Edmund Tsui, MD, social media editor for Ophthalmology, discusses some of the common pitfalls and advantages in the manner some physicians and clinicians navigate social media on this episode of the DocTalk Podcast.

Carl Regillo, MD, of Wills Eye Hospital, presented end of study results of the phase 2 LADDER study, which suggested PDS with ranibizumab could be an effective treatment for neovascular AMD, at AAO 2019.

A new study from the University of Western Australia has revealed that undergoing cataract surgery on both eyes resulted in a 48% improvement in safety during a driving simulator with patients.

A 2-year study in 80 children found that combination therapy of orthokeratology and atropine 0.01% was 38% more effective than monotherapy for slowing myopia in children with lower myopia.

Louis Pasquale, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, discusses how technology and artificial intelligence has impacted ophthalmology.

Results of the LEAVO trial presented at AAO 2019 reveal a low level of confidence among investigators for recommending bevacizumab treatment as equivalent to ranibizumab and aflibercept at 100 weeks.

A phase 2 trial found that use of risuteganib resulted in 48% of patients with nonexudative age-related macular degeneration gaining 8 or more letters of BCVA.

A new study presented at AAO 2019 found the only FDA-approved pill for interstitial cystitis caused retinal damage in about 25% of patients who had been receiving the treatment.

Data from 2 phase 3 trials, which included more than 1800 patients, examining the efficacy and safety profile of abicipar for the treatment of neovascular age-related macular degeneration were presented at AAO 2019.

Data from a phase 1/2a study show RGX-314, a gene therapy from RegenX, was well tolerated and improved visual acuity in patients.

Results of the phase 1 OPTIC trial reveal ADVM-022 was effective at maintaining visual acuity in patients with wet AMD with a favorable safety profile.

Rishi Singh, MD, staff physician at Cole Eye Institute, discusses the most common myths he sees surrounding diabetic macular edema and its treatment.

A new study from investigators in Australia has found nearly 1 in 5 patients in a cardiac rehabilitation program suffer from at least moderate depression, anxiety, or stress.

A recent study has found the long-term risk of developing thromboembolism with postoperative atrial fibrillation was similar to that of nonsurgical, nonvalvular atrial fibrillation.

A new study from the European Heart Journal is contradicting a January 2019 FDA warning that paclitaxel-coated devices were linked to an increased risk of death.

Novartis has announced the wet age-related macular degeneration treatment brolucizumab, which was backed by data from the HAWK and HARRIER trials, has received FDA approval.

A new study which reviewed data on more than 3 million patients found dog ownership was associated with a 24% reduced risk of all-cause mortality and a 65% reduced risk of mortality after a heart attack.

A recent study of primary practices in England found Asian patients were 15% less likely to be prescribed insulin, while black patients were half as likely to be prescribed a GLP-1 agonist or SGLT2 inhibitor.

George Bakris, MD, professor of medicine at University of Chicago Medicine and member of CREDENCE steering committee, discusses the recent approval of canagliflozin and what it means for diabetic patients and their physicians.

A new study of children in West Virginia found associations birth weight and blood pressure as well as cholesterol and triglycerides at age 11.

The United States Food and Drug Administration has accepted a BLA for Viaskin Peanut from DBV Technologies for the treatment of peanut-allergic children ages 4 to 11, which previously withdrew a BLA in 2018 after request from the FDA requested additional data on its manufacturing procedures and quality controls.

A new study from the Harvard T.H. Chan School of Public Health found increasing consumption of sugary beverages, including 100% fruit juices, by half a serving per day could increase a person's risk of diabetes by 16%.

A recent study from the ACC Middle East Conference 2019 found patients with hypertension and type 2 diabetes who consume a high fiber diet had improvement in their blood pressure, cholesterol and fasting glucose.

A new study from the Ohio State University found the commonly-prescribed blood cancer drug ibrutinib was linked to new or worsening hypertension, which investigators suggest could contribute to an increase in other cardiovascular events.

A study from investigators in Europe found the CCS, ACC/AHA, and NICE guidelines for statin use may be more effective at preventing ASCVD events than ESC/EAS or USPSTF guidelines.